Literature DB >> 7577615

Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission.

K Tobal1, P R Johnson, M J Saunders, C J Harrison, J A Liu Yin.   

Abstract

The pericentric inversion of chromosome 16 [inv(16)(p13q22)] and t(16;16)(p13;q22) are chromosomal rearrangements frequently associated with AML FAB type M4Eo resulting in the production of a fusion gene CBFB/MYH11. We studied 17 patients with a chromosome 16 abnormality (eight M4Eo, two M1, one M2, three M4 without abnormal eosinophils, three MDS) for the presence of CBFB/MYH11 transcripts using an RT-PCR technique. 10 AML patients with inv(16) tested RT-PCR positive (eight at presentation, one in remission, one in remission and relapse). Three of these patients were originally reported by cytogenetic analysis to have del(16q22) but the positive RT-PCR results prompted a cytogenetic re-examination, resulting in the correction of the reports to inv(16). We show that although inv(16) is closely associated with AML M4Eo, it can also be detected in cases of AML M4 without abnormal eosinophils. Three cases of MDS with inv(16) were also RT-PCR positive. Four patients with other chromosome 16 abnormalities were RT-PCR negative. Four AML patients with inv(16) were studied in remission. All were RT-PCR positive, including one patient in remission for 108 months and one 22 months post allogeneic bone marrow transplant. In the latter two remission patients, RT-PCR evaluation was positive in bone marrow (BM) but not in peripheral blood, suggesting that BM may be the more informative. We conclude that this technique is valuable in the accurate molecular classification of AML, particularly as treatment options may be influenced by such information. Though RT-PCR is highly sensitive in detecting CBFB/MYH11 fusion transcripts during remission, monitoring of minimal residual disease in patients with inv(16) remains to be established.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7577615     DOI: 10.1111/j.1365-2141.1995.tb05253.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

1.  Comprehensive review of adult acute myelogenous leukemia: cytomorphological, enzyme cytochemical, flow cytometric immunophenotypic, and cytogenetic findings.

Authors:  C H Dunphy
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

2.  Childhood acute myeloid leukemia with bone marrow eosinophilia caused by t(16;21)(q24;q22).

Authors:  Nozomu Kawashima; Akira Shimada; Takeshi Taketani; Yasuhide Hayashi; Nao Yoshida; Kimikazu Matsumoto; Yoshiyuki Takahashi; Seiji Kojima; Koji Kato
Journal:  Int J Hematol       Date:  2012-03-09       Impact factor: 2.490

3.  Inversion of chromosome 16 in accelerated phase of chronic myeloid leukaemia: report of a case and review of the literature.

Authors:  M Colović; G Janković; J Bila; V Djordjević; P H Wiernik
Journal:  Med Oncol       Date:  1998-09       Impact factor: 3.064

4.  Comprehensive analysis of CBFbeta-MYH11 fusion transcripts in acute myeloid leukemia by RT-PCR analysis.

Authors:  ShriHari S Kadkol; Annette Bruno; Carol Dodge; Valerie Lindgren; Farhad Ravandi
Journal:  J Mol Diagn       Date:  2004-02       Impact factor: 5.568

5.  Fluorescence in situ hybridization identifies cryptic t(16;16)(p13;q22) masked by del(16)(q22) in a case of AML-M4 Eo.

Authors:  Shakil H Merchant; Skip Haines; Bryan Hall; John Hozier; David S Viswanatha
Journal:  J Mol Diagn       Date:  2004-08       Impact factor: 5.568

6.  Monitoring AML1-ETO and CBFbeta-MYH11 transcripts in acute myeloid leukemia.

Authors:  John A Liu Yin; Lindsay Frost
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

7.  Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.

Authors:  Philippe Armand; Haesook T Kim; Daniel J DeAngelo; Vincent T Ho; Corey S Cutler; Richard M Stone; Jerome Ritz; Edwin P Alyea; Joseph H Antin; Robert J Soiffer
Journal:  Biol Blood Marrow Transplant       Date:  2007-03-21       Impact factor: 5.742

Review 8.  Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results.

Authors:  Vijaya Raj Bhatt; Hagop Kantarjian; Jorge E Cortes; Farhad Ravandi; Gautam Borthakur
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-12-21

9.  MicroRNAs in Myeloid Hematological Malignancies.

Authors:  Maria Ciccone; George Adrian Calin
Journal:  Curr Genomics       Date:  2015-10       Impact factor: 2.236

Review 10.  Core binding factor acute myelogenous leukemia-2021 treatment algorithm.

Authors:  Gautam Borthakur; Hagop Kantarjian
Journal:  Blood Cancer J       Date:  2021-06-16       Impact factor: 11.037

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.